Skip to content
2000
image of In Vitro, In Vivo and Ex VivoIrradiation Research of Low-frequency Ultrasound Combined with Chemotherapy for Ovarian Carcinoma Cells

Abstract

Introduction

To investigate the effects of 20 kHz low-frequency ultrasound irradiation-mediated microbubbles (USMB) combined with chemotherapy paclitaxel and cisplatin (PC) on ovarian cancer cells.

Methods

In the research, ovarian cancer cell lines were divided into four groups: control, USMB, PC, and USMB+PC. The cell membrane structure was observed using scanning electron microscopy (SEM). A TUNEL assay was used to investigate cell apoptosis. In the study, USMB+PC was used to treat the ascites in the nude mice. The ascites volumes were calculated by magnetic resonance imaging. In the research, ascites samples of clinical ovarian cancer patients were collected and focused with USMB+PC and observed by liquid-based cytology.

Results

SEM revealed cell wall defects in the USMB and USMB+PC, with pores ranging from 5 to 15 μm in diameter. The USMB+PC had the highest apoptosis rate, with statistical differences compared to the other three groups (all <0.05). After USMB+PC treatment, the volume of ascites in the nude mice decreased (t=3.6, =0.0228). In the USMB+PC, tumour cells in the ascites showed obvious degeneration and necrosis.

Discussion

The mechanism is that US irradiation causes MBs to rupture, generating shock waves, damaging tumor cell walls, forming pores (sonoporation), leading to more drugs entering cancer cells. The clinical significance of this technology is that it can increase the dosage of locally targeted tumor cells, reduce systemic chemotherapy use/or the clinical dosage of chemotherapy drugs, and decrease the toxic side effects on normal tissue cells. The limitation is that there are relatively few cases of patients with ascites. Future research direction is US irradiation on ascites of ovarian cancer patients with different histological types.

Conclusion

US cavitation and chemotherapy inhibit ovarian cancer cells.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673373712251125070653
2026-03-04
2026-03-08

  • From This Site

    /content/journals/cmc/10.2174/0109298673373712251125070653
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Armstrong D.K. Alvarez R.D. Backes F.J. Bakkum-Gamez J.N. Barroilhet L. Behbakht K. Berchuck A. Chen L. Chitiyo V.C. Cristea M. DeRosa M. Eisenhauer E.L. Gershenson D.M. Gray H.J. Grisham R. Hakam A. Jain A. Karam A. Konecny G.E. Leath C.A. III Leiserowitz G. Liu J. Martin L. Matei D. McHale M. McLean K. Miller D.S. Percac-Lima S. Remmenga S.W. Schorge J. Stewart D. Thaker P.H. Vargas R. Hendrickson A.W. Werner T.L. Zsiros E. Dwyer M.A. Hang L. NCCN Guidelines® insights: Ovarian cancer, version 3. J. Natl. Compr. Canc. Netw. 2022 20 9 972 980 10.6004/jnccn.2022.0047 36075393
    [Google Scholar]
  2. Feng J. Xu L. Chen Y. Lin R. Li H. He H. Trends in incidence and mortality for ovarian cancer in china from 1990 to 2019 and its forecasted levels in 30 years. J. Ovarian Res. 2023 16 1 139 10.1186/s13048‑023‑01233‑y 37452315
    [Google Scholar]
  3. Cui LW. Shen ZY. MRI appearances of stage IA ovarian carcinoma. Curr. Med. Imaging. 2023 10.2174/1573405619666230306102912 36876842
    [Google Scholar]
  4. Cui L Zhu XH Fan LY Zhang L Shen Z CT findings of stage IA ovarian cancer: Comparison between borderline tumor and stage IC ovarian cancer. Curr. Med. Imaging. 2023 10.2174/0115734056251322231024071757 37921155
    [Google Scholar]
  5. Monavarian M. Elhaw A.T. Tang P.W. Javed Z. Shonibare Z. Scalise C.B. Arend R. Jolly M.K. Sewell- Loftin M.K. Hempel N. Mythreye K. Emerging perspectives on growth factor metabolic relationships in the ovarian cancer ascites environment. Semin. Cancer Biol. 2022 86 Pt 2 709 719 10.1016/j.semcancer.2022.03.004 35259492
    [Google Scholar]
  6. Qi Y. Zhang Y. Shi Y. Yao S. Dai M. Cai H. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for platinum-sensitive recurrence epithelial ovarian cancer with HRR mutation: A phase III randomized clinical trial. Technol. Cancer Res. Treat. 2023 21 10.1177/15330338221104565 35929135
    [Google Scholar]
  7. Lim P.Q. Han I.H. Seow K.M. Chen K.H. Hyperthermic intraperitoneal chemotherapy (HIPEC): An overview of the molecular and cellular mechanisms of actions and effects on epithelial ovarian cancers. Int. J. Mol. Sci. 2022 23 17 10078 10.3390/ijms231710078 36077477
    [Google Scholar]
  8. Aronson S.L. Lopez-Yurda M. Koole S.N. Schagen van Leeuwen J.H. Schreuder H.W.R. Hermans R.H.M. de Hingh I.H.J.T. van Gent M.D.J.M. Arts H.J.G. van Ham M.A.P.C. van Dam P.A. Vuylsteke P. Aalbers A.G.J. Verwaal V.J. Van de Vijver K.K. Aaronson N.K. Sonke G.S. van Driel W.J. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): Final survival analysis of a randomised, controlled, phase 3 trial. Lancet Oncol. 2023 24 10 1109 1118 10.1016/S1470‑2045(23)00396‑0 37708912
    [Google Scholar]
  9. Lim M.C. Chang S.J. Park B. Yoo H.J. Yoo C.W. Nam B.H. Park S.Y. Seo S-S. Kang S. Yun J.Y. Cho D-S. Kim S.H. Kim T-S. Park S.S. Lee D.W. Park S.C. Park H.M. Han S-S. Kim S.H. Yang H.C. Kim M.S. Lee J.M. Eom B.W. Kim Y.I. Yoon H.M. Choi I.J. Kim S.H. Joung J.Y. Seo H.K. Joo J.N. Song Y.J. Park S.H. Jung D.C. Kim M.J. Park J.W. Jeong S-Y. Yun Y.H. Park S. Bristow R.E. HIPEC for Ovarian Cancer Collaborators Survival after hyperthermic intraperitoneal chemotherapy and primary or interval cytoreductive surgery in ovarian cancer. JAMA Surg. 2022 157 5 374 383 10.1001/jamasurg.2022.0143 35262624
    [Google Scholar]
  10. Sugarbaker P.H. Optimizing regional chemotherapy for epithelial ovarian cancer. J. Obstet. Gynaecol. Res. 2022 48 6 1306 1317 10.1111/jog.15224 35343033
    [Google Scholar]
  11. Manzanedo I. Pereira F. Serrano Á. Pérez-Viejo E. Martínez-Torres B. Carrión L. Calzas J. The use of cisplatin plus doxorubicin or paclitaxel in hyperthermic intraperitoneal chemotherapy (HIPEC) for stage IIIC or IV epithelial ovarian cancer: A comparative study. Clin. Transl. Oncol. 2019 21 10 1357 1363 10.1007/s12094‑019‑02065‑3 30788835
    [Google Scholar]
  12. Rueth N.M. Murray S.E. Huddleston S.J. Abbott A.M. Greeno E.W. Kirstein M.N. Tuttle T.M. Severe electrolyte disturbances after hyperthermic intraperitoneal chemotherapy: Oxaliplatin versus mitomycin C. Ann. Surg. Oncol. 2011 18 1 174 180 10.1245/s10434‑010‑1210‑1 20614192
    [Google Scholar]
  13. Villarejo Campos P. Sánchez García S. Amo-Salas M. García Santos E. López de la Manzanara C. Alberca A. Padilla-Valverde D. Redondo Calvo F.J. Martín J. Paclitaxel as HIPEC-drug after surgical cytoreduction for ovarian peritoneal metastases: A randomized phase III clinical trial (HIPECOVA). Curr. Oncol. 2024 31 2 660 671 10.3390/curroncol31020048 38392042
    [Google Scholar]
  14. Neveu J. Tremblay E. Mercier F. Garneau S. Cormier B. Developing a hyperthermic intraperitoneal chemotherapy (HIPEC) gynecologic oncology program: A Canadian experience. Int. J. Gynecol. Cancer 2023 33 12 1957 1965 10.1136/ijgc‑2023‑004788 38011988
    [Google Scholar]
  15. Chambers L.M. Costales A.B. Crean-Tate K. Kuznicki M. Morton M. Horowitz M. Jagielo T. Rose P.G. Michener C. Vargas R. Debernardo R. A guide to establishing a hyperthermic intraperitoneal chemotherapy program in gynecologic oncology. Gynecol. Oncol. 2020 158 3 794 802 10.1016/j.ygyno.2020.06.487 32624234
    [Google Scholar]
  16. Goodman M.D. McPartland S. Detelich D. Saif M.W. Chemotherapy for intraperitoneal use: A review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy. J. Gastrointest. Oncol. 2016 7 1 45 57 26941983
    [Google Scholar]
  17. Praiss A.M. Moukarzel L.A. Zivanovic O. Is there a role for hyperthermic intraperitoneal chemotherapy in ovarian cancer? Curr. Opin. Obstet. Gynecol. 2023 35 1 21 26 10.1097/GCO.0000000000000837 36595646
    [Google Scholar]
  18. Ren W.W. Xu S.H. Sun L.P. Zhang K. Ultrasound-based drug delivery system. Curr. Med. Chem. 2022 29 8 1342 1351 10.2174/0929867328666210617103905 34139971
    [Google Scholar]
  19. Li F. Huang C. Zhang X. Wang C. Hu J. Chen S. Tian H. Shen Z. Guo J. Lin S. Cavitation bubble structures below a soft boundary in an ultrasonic field. Ultrason. Sonochem. 2023 98 106500 10.1016/j.ultsonch.2023.106500 37413916
    [Google Scholar]
  20. Fan C.H. Tsai C.Y. Lai C.Y. Liou Y.F. Lee J.K. Yeh C.K. Feasibility of in vitro calcification plaque disruption using ultrasound-induced microbubble inertial cavitation. Ultrasonics 2024 138 107238 10.1016/j.ultras.2023.107238 38183758
    [Google Scholar]
  21. Li F. Huang C. Zhang X. Wang C. Guo J. Lin S. Shen Z. Tian H. Structure of bubble cluster adjacent to the water surface in the ultrasonic field. Ultrasonics 2023 132 106992 10.1016/j.ultras.2023.106992 37018933
    [Google Scholar]
  22. Gharat S.K. Godiyal S.C. Malusare P.P. Jadhav K.R. Kadam V.J. Microbubbles contrast agents: General overview as diagnostics and therapeutic agent. Curr. Drug Targets 2022 23 10 960 977 10.2174/1573399818666220421123142 35593356
    [Google Scholar]
  23. Cui L.W. Fan L.Y. Shen Z.Y. Application research progress of nanomaterial graphene and its derivative complexes in tumor diagnosis and therapy. Curr. Med. Chem. 2024 31 39 6436 6459 10.2174/0109298673251648231106112354 38299292
    [Google Scholar]
  24. Wang L. Zheng S. Advances in low-frequency ultrasound combined with microbubbles in targeted tumor therapy. J. Zhejiang Univ. Sci. B 2019 20 4 291 299 10.1631/jzus.B1800508 30932374
    [Google Scholar]
  25. Kip B. Aydin O. Overcome of cisplatin resistance in ovarian cancer by combination of low-intensity ultrasound and cisplatin. Curr. Drug Deliv. 2023 20 9 1380 1390 10.2174/1567201819666220627100857 35761504
    [Google Scholar]
  26. Shamaeizadeh A. Beigi A. Naghib S.M. Tajabadi M. Rahmanian M. Mozafari M.R. Smart nanobiomaterials for gene delivery in localized cancer therapy: An overview from emerging materials and devices to clinical applications. Curr. Cancer Drug Targets 2024 38644713
    [Google Scholar]
  27. Lu S. Zhao P. Deng Y. Liu Y. Mechanistic insights and therapeutic delivery through micro/nanobubble-assisted ultrasound. Pharmaceutics 2022 14 3 480 10.3390/pharmaceutics14030480 35335857
    [Google Scholar]
  28. Fan C.H. Huang E. Lo W.C. Yeh C.K. Ultrasound-cavitation-enhanced drug delivery via microbubble clustering induced by acoustic vortex tweezers. Ultrason. Sonochem. 2025 114 107273 10.1016/j.ultsonch.2025.107273 39979196
    [Google Scholar]
  29. Eck M. Aronovich R. Ilovitsh T. Efficacy optimization of low frequency microbubble-mediated sonoporation as a drug delivery platform to cancer cells. Int. J. Pharm. X 2022 4 100132 10.1016/j.ijpx.2022.100132 36189459
    [Google Scholar]
  30. Nittayacharn P. Abenojar E. Cooley M.B. Berg F.M. Counil C. Sojahrood A.J. Khan M.S. Yang C. Berndl E. Golczak M. Kolios M.C. Exner A.A. Efficient ultrasound-mediated drug delivery to orthotopic liver tumors – Direct comparison of doxorubicin-loaded nanobubbles and microbubbles. J. Control. Release 2024 367 135 147 10.1016/j.jconrel.2024.01.028 38237687
    [Google Scholar]
  31. Hourani W. Deb P.K. Alhawamdeh M. Al-Shari N. Borah P. Dahabiyeh L.A. Jaber A.Y. P N. S S. Dasappa J.P. Venugopala K.N. Anticancer and cyclooxygenase inhibitory activity of benzylidene derivatives of fenobam and its thio analogues. Curr. Med. Chem. 2024 32 10.2174/0109298673345068241120045638 39686634
    [Google Scholar]
  32. Hu H. Zhu S. Tong Y. Huang G. Tan B. Yang L. Antitumor activity of triptolide in SKOV3 cells and SKOV3/DDP in vivo and in vitro. Anticancer Drugs 2020 31 5 483 491 10.1097/CAD.0000000000000894 31972592
    [Google Scholar]
  33. Shen Z.Y. Xia G.L. Wu M.F. Shi M.X. Qiang F.L. Shen E. Hu B. The effects of low-frequency ultrasound and microbubbles on rabbit hepatic tumors. Exp. Biol. Med. 2014 239 6 747 757 10.1177/1535370214525320 24719377
    [Google Scholar]
  34. Shen Z.Y. Xia G.L. Wu M.F. Ji L.Y. Li Y.J. The effects of percutaneous ethanol injection followed by 20-kHz ultrasound and microbubbles on rabbit hepatic tumors. J. Cancer Res. Clin. Oncol. 2016 142 2 373 378 10.1007/s00432‑015‑2034‑y 26306908
    [Google Scholar]
  35. Zhao P. Peng Y. Wang Y. Hu Y. Qin J. Li D. Yan K. Fan Z. Mechanistic study of ultrasound and microbubble enhanced cancer therapy in a 3D vascularized microfluidic cancer model. Ultrason. Sonochem. 2023 101 106709 10.1016/j.ultsonch.2023.106709 38043461
    [Google Scholar]
  36. Vince J. Lewis A. Stride E. High-speed imaging of microsphere transport by cavitation activity in a tissue-mimicking phantom. Ultrasound Med. Biol. 2023 49 6 1415 1421 10.1016/j.ultrasmedbio.2023.01.025 36931999
    [Google Scholar]
  37. Jiang Q. Yang M. Qu Z. Zhou J. Zhang Q. Resveratrol enhances anticancer effects of paclitaxel in HepG2 human liver cancer cells. BMC Complement. Altern. Med. 2017 17 1 477 10.1186/s12906‑017‑1956‑0 28978315
    [Google Scholar]
  38. Huang T. Gong W. Li X. Zou C. Jiang G. Li X. Feng D. Enhancement of osteosarcoma cell sensitivity to cisplatin using paclitaxel in the presence of hyperthermia. Int. J. Hyperthermia 2013 29 3 248 255 10.3109/02656736.2013.775511 23527624
    [Google Scholar]
  39. Gurunathan S. Kim J.H. Graphene oxide enhances biogenesis and release of exosomes in human ovarian cancer cells. Int. J. Nanomedicine 2022 17 5697 5731 10.2147/IJN.S385113 36466784
    [Google Scholar]
  40. Tan J.L. Djayakarsana D. Wang H. Chan R.W. Bailey C. Lau A.Z. Deuterium MRS of early treatment‐induced changes in tumour lactate in vitro. NMR Biomed. 2021 34 12 e4599 10.1002/nbm.4599 34405471
    [Google Scholar]
  41. Yamashita K. Suetsugu A. Hayashi S. Shimizu M. Hoffman R.M. Exosome transfer between different co-implanted human pancreatic cancer cell lines occurs in the primary tumor and multiple metastatic sites of nude mice but not in co-culture in vitro. Anticancer Res. 2024 44 8 3307 3315 10.21873/anticanres.17149 39060068
    [Google Scholar]
  42. Tang J. Zhu J. Ye Y. Liu Y. He Y. Zhang L. Tang D. Qiao C. Feng X. Li J. Kan Y. Li X. Jin X. Kong D. Inhibition LC3B can increase chemosensitivity of ovarian cancer cells. Cancer Cell Int. 2019 19 1 199 10.1186/s12935‑019‑0921‑z 31384174
    [Google Scholar]
  43. Ma Y. Xun J. Wang BT. Li DH. Zhang Q. Wang ZY. Wu Y. Effect of Xuanfu Daizhe decoction on stemness of esophageal cancer cells. Zhongguo Ying Yong Sheng Li Xue Za Zhi 2022 38 1 62 67 10.12047/j.cjap.6228.2022.012 35634672
    [Google Scholar]
  44. Tabata S. Kojima Y. Sakamoto T. Igarashi K. Umetsu K. Ishikawa T. Hirayama A. Kajino-Sakamoto R. Sakamoto N. Yasumoto K. Okano K. Suzuki Y. Yachida S. Aoki M. Soga T. L-2hydroxyglutaric acid rewires amino acid metabolism in colorectal cancer via the mTOR-ATF4 axis. Oncogene 2023 42 16 1294 1307 10.1038/s41388‑023‑02632‑7 36879117
    [Google Scholar]
  45. Wu M. Cheng X. Wang D. Lai Y. Li H. Ye Y. Peng Y. Chen Q. Zhang B. Lin Z. Li J. Determining the maximum tolerated dose of paclitaxel combined with fixed dose of cisplatin for hyperthermic intraperitoneal chemotherapy in ovarian cancer: A multicenter phase I trial. Gynecol. Oncol. 2024 181 125 132 10.1016/j.ygyno.2023.12.019 38159362
    [Google Scholar]
  46. Shidham V.B. Collection and processing of effusion fluids for cytopathologic evaluation. Cytojournal 2022 19 5 10.25259/CMAS_02_14_2021 35541031
    [Google Scholar]
  47. Shen ZY Jiang YM Zhou YF Si HF Wang L High-speed photographic observation of the sonication of a rabbit carotid artery filled with microbubbles by 20-kHz low frequency ultrasound. Ultrason Sonochem 2018 40 Pt A 980 987 10.1016/j.ultsonch.2017.09.015 28946510
    [Google Scholar]
  48. Ding Q. Niu P. Zhu Y. Chen H. Shi D. Cardamonin inhibits the expression of P-glycoprotein and enhances the anti-proliferation of paclitaxel on SKOV3-Taxol cells. J. Nat. Med. 2022 76 1 220 233 10.1007/s11418‑021‑01583‑1 34751899
    [Google Scholar]
  49. Smith E.R. Wang J.Q. Yang D.H. Xu X.X. Paclitaxel resistance related to nuclear envelope structural sturdiness. Drug Resist. Updat. 2022 65 100881 10.1016/j.drup.2022.100881 36368286
    [Google Scholar]
  50. Ghosh S. Cisplatin: The first metal based anticancer drug. Bioorg. Chem. 2019 88 102925 10.1016/j.bioorg.2019.102925 31003078
    [Google Scholar]
  51. Yang M. Liu Y. Han Y. Zhang W. Zhang H. Yang S. Mitochondrial translocation of P66Shc aggravates cisplatin-induced AKI by promoting ferroptosis. Curr. Med. Chem. 2023 30 6 744 756 10.2174/0929867329666220819112808 35986536
    [Google Scholar]
  52. Zhong W. Chen X. Jiang P. Wan J.M.F. Qin P. Yu A.C.H. Induction of endoplasmic reticulum stress by sonoporation: Linkage to mitochondria-mediated apoptosis initiation. Ultrasound Med. Biol. 2013 39 12 2382 2392 10.1016/j.ultrasmedbio.2013.08.005 24063957
    [Google Scholar]
  53. Al Rifai N. Desgranges S. Le Guillou-Buffello D. Giron A. Urbach W. Nassereddine M. Charara J. Contino-Pépin C. Taulier N. Ultrasound-triggered delivery of paclitaxel encapsulated in an emulsion at low acoustic pressures. J. Mater. Chem. B Mater. Biol. Med. 2020 8 8 1640 1648 10.1039/C9TB02493J 32011617
    [Google Scholar]
  54. Bernard V. Škorpíková J. Mornstein V. Slaninová I. Biological effects of combined ultrasound and cisplatin treatment on ovarian carcinoma cells. Ultrasonics 2010 50 3 357 362 10.1016/j.ultras.2009.08.010 19740505
    [Google Scholar]
  55. Bernard V. Mornstein V. Bourek A. Effect of near field ultrasound on carboplatin treatment of ovarian carcinoma cells. Indian J. Biochem. Biophys. 2013 50 4 284 288 [J]. 24772947
    [Google Scholar]
  56. Yang T. Zhang Y. Wang T. Li M. Zhang Y. Zhao D. Xu L. Wang X. Low-frequency ultrasound irradiation increases paclitaxel-induced sarcoma cells apoptosis and facilitates the transmembrane delivery of drugs. Front. Pharmacol. 2022 13 1065289 10.3389/fphar.2022.1065289 36582521
    [Google Scholar]
  57. Cao J. Hu C. Zhou H. Qiu F. Chen J. Zhang J. Huang P. Microbubble-mediated cavitation promotes apoptosis and suppresses invasion in AsPC-1 Cells. Ultrasound Med. Biol. 2021 47 2 323 333 10.1016/j.ultrasmedbio.2020.10.014 33221141
    [Google Scholar]
  58. Bismuth M. Katz S. Mano T. Aronovich R. Hershkovitz D. Exner A.A. Ilovitsh T. Low frequency nanobubble-enhanced ultrasound mechanotherapy for noninvasive cancer surgery. Nanoscale 2022 14 37 13614 13627 10.1039/D2NR01367C 36070492
    [Google Scholar]
  59. Shen Z. Shao J. Zhang J. Qu W. Ultrasound cavitation enhanced chemotherapy: In vivo research and clinical application. Exp. Biol. Med. 2020 245 14 1200 1212 10.1177/1535370220936150 32567346
    [Google Scholar]
  60. Bitar R. Leung G. Perng R. Tadros S. Moody A.R. Sarrazin J. McGregor C. Christakis M. Symons S. Nelson A. Roberts T.P. MR pulse sequences: What every radiologist wants to know but is afraid to ask. Radiographics 2006 26 2 513 537 10.1148/rg.262055063 16549614
    [Google Scholar]
  61. Hao Q. Liu Q. Wang X. Wang P. Li T. Tong W.Y. Membrane damage effect of therapeutic ultrasound on ehrlich ascitic tumor cells. Cancer Biother. Radiopharm. 2009 24 1 41 48 10.1089/cbr.2008.0495 19243247
    [Google Scholar]
  62. Wang P. Wang X. Liu Q. Cell damage of hepatoma-22 cells exposed to continuous wave ultrasound. Tumori 2012 98 4 523 531 10.1177/030089161209800419 23052171
    [Google Scholar]
  63. Ivone M. Pappalettere C. Watanabe A. Tachibana K. Study of cellular response induced by low intensity ultrasound frequency sweep pattern on myelomonocytic lymphoma U937 cells. J. Ultrasound 2016 19 3 167 174 10.1007/s40477‑016‑0199‑0 27635161
    [Google Scholar]
  64. Yoshida T. Kondo T. Ogawa R. Feril L.B. Jr Zhao Q.L. Watanabe A. Tsukada K. Combination of doxorubicin and low-intensity ultrasound causes a synergistic enhancement in cell killing and an additive enhancement in apoptosis induction in human lymphoma U937 cells. Cancer Chemother. Pharmacol. 2008 61 4 559 567 10.1007/s00280‑007‑0503‑y 17505825
    [Google Scholar]
  65. Jung E.J. Eom H.M. Byun J.M. Kim Y.N. Lee K.B. Sung M.S. Kim K.T. Jeong D.H. Different features of the histopathological subtypes of ovarian tumors in pre- and postmenopausal women. Menopause 2017 24 9 1028 1032 10.1097/GME.0000000000000976 28832426
    [Google Scholar]
  66. Zhang, H.; Chen, Y.X.; Guo, L.Y. The value of preoperative LAR in predicting the prognosis of patients with epithelial ovarian cancer and the construction and evaluation of prognostic nomogram model. J. Mod. Oncol. 2025 33 7 1190 1198
    [Google Scholar]
  67. Coosemans Baert T. D’Heygere V. Wouters R. De Laet L. Van Hoylandt A. Thirion G. Ceusters J. Laenen A. Vandecaveye V. Vergote I. Increased immunosuppression is related to increased amounts of ascites and inferior prognosis in ovarian cancer. Anticancer Res. 2019 39 11 5953 5962 10.21873/anticanres.13800 31704820
    [Google Scholar]
  68. Levin G. Gotlieb W.H. Interleukine-10 in ovarian cancer. Chin. Clin. Oncol. 2024 13 4 48 10.21037/cco‑23‑135 38735685
    [Google Scholar]
  69. Rodrigues I.S.S. Martins-Filho A. Micheli D.C. Lima C.A. Tavares-Murta B.M. Murta E.F.C. Nomelini R.S. IL-6 and IL-8 as prognostic factors in peritoneal fluid of ovarian cancer. Immunol. Invest. 2020 49 5 510 521 10.1080/08820139.2019.1691222 31755326
    [Google Scholar]
  70. Aquino-Acevedo A.N. Knochenhauer H. Castillo-Ocampo Y. Ortiz-León M. Rivera-López Y.A. Morales-López C. Cruz-Robles M.E. Hernández-Cordero E.R. Russell S. Whitaker R. Bonilla-Claudio M. Chen D.T. Dutil J. Gaillard S.L. Yi J.S. Previs R.A. Armaiz-Pena G.N. Stress hormones are associated with inflammatory cytokines and attenuation of T-cell function in the ascites from patients with high grade serous ovarian cancer. Brain Behav. Immun. Health 2022 26 100558 10.1016/j.bbih.2022.100558 36439058
    [Google Scholar]
  71. Li M. Zhu Y. Yang C. Yang M. Ran H. Zhu Y. Zhang W. Acoustic triggered nanobomb for US imaging guided sonodynamic therapy and activating antitumor immunity. Drug Deliv. 2022 29 1 2177 2189 10.1080/10717544.2022.2095058 35815688
    [Google Scholar]
  72. Kotopoulis S. Lam C. Haugse R. Snipstad S. Murvold E. Jouleh T. Berg S. Hansen R. Popa M. Mc Cormack E. Gilja O.H. Poortinga A. Formulation and characterisation of drug-loaded antibubbles for image-guided and ultrasound-triggered drug delivery. Ultrason. Sonochem. 2022 85 105986 10.1016/j.ultsonch.2022.105986 35358937
    [Google Scholar]
/content/journals/cmc/10.2174/0109298673373712251125070653
Loading
In Vitro, In Vivo and Ex VivoIrradiation Research of Low-frequency Ultrasound Combined with Chemotherapy for Ovarian Carcinoma Cells
Bentham Science Publishers ; https://doi.org/10.2174/0109298673373712251125070653
/content/journals/cmc/10.2174/0109298673373712251125070653
/content/journals/cmc/10.2174/0109298673373712251125070653
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: paclitaxel ; ovarian carcinoma ; cavitation ; Ultrasound ; cisplatin ; microbubble

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test